DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

A Diabetes Outcomes Progression Trial



Design and Objectives

ADOPT was designed to evaluate the long-term efficacy of monotherapy with rosiglitazone on glycaemic control and on the progression of pathophysiological abnormalities associated with type 2 diabetes, as compared with metformin or glibenclamide (glyburide) monotherapy, in patients recently diagnosed with type 2 diabetes. The primary assessment of treatment effectiveness is the time from randomisation to monotherapy failure. It is expected that ADOPT will provide data on the effects of mechanistically differing treatment options on metabolic control, beta-cell function, and markers of macrovascular disease risk in type 2 diabetes.

Primary inclusion criteria

Primary exclusion criteria